Unique ID issued by UMIN | UMIN000005889 |
---|---|
Receipt number | R000006933 |
Scientific Title | The safety and efficacy of tocilizumab in patients with neuromyelitis optica |
Date of disclosure of the study information | 2011/07/08 |
Last modified on | 2014/11/27 16:56:19 |
The safety and efficacy of tocilizumab in patients with neuromyelitis optica
Tocilizumab in patients with neuromyelitis optica
The safety and efficacy of tocilizumab in patients with neuromyelitis optica
Tocilizumab in patients with neuromyelitis optica
Japan |
neuromyelitis optica
Neurology |
Others
NO
The purpose of this study is to evaluate safety and efficacy of anti-IL-6R antibody tocilizumab in intractable neuromyelitis optica and to explore mechanism underlying its effectiveness.
Safety,Efficacy
Confirmatory
Explanatory
Not applicable
An improvement in MRI lesions, relapsing rate, and EDSS at baseline and 6 months thereafter.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 months.
20 | years-old | <= |
65 | years-old | >= |
Male and Female
Diagnosis of neuromyelitis optica (NMO), as defined by 2006 criteria published in NEUROLOGY vol. 66 or NMO seropositive spectrum disorder (recurrent optic neuritis or longitudinally extensive transverse myelitis). All patients must be anti-aquaporin 4 antibody seropositive.
Patients with intractable NMO who are resistant to the standard therapy or experiencing sever adverse reactions of the current therapy.
Provision of written informed consent to participate in this study.
1) Patients with severe infection such as tuberculosis, pneumocystis carinii pneumonia, nontuberculous mycobacterial infection, hepatitis B, hepatitis C, or chronic active EB virus infection.
2) Patients with a history of tuberculosis infection or patients with pleural thickness or old tuberculin in chest X-ray.
3) Patients with a history of hypersensitivity to this drug.
4) Patients with a history of intestinal diverticulum.
5) Patients with interstitial pneumonitis.
6) Patients with leukopenia (white blood cell number < 4000/mm3), lymphopenia (lymphocyte number < 1000/mm3) or seropositivity for beta-D-glucan in peripheral blood.
7) Pregnant women or patients with possible pregnancy.
8) Patients who can not provide consent to participate in this study by themselves.
9) Patients whose EDSS are more than 7.
3
1st name | |
Middle name | |
Last name | Takashi Yamamura |
National Institute of Neuroscience, NCNP
Department of Immunology
4-1-1, Ogawahigashi, Kodaira, Tokyo 187-8502, Japan
042-341-2711
yamamura@ncnp.go.jp
1st name | |
Middle name | |
Last name | Takashi Yamamura |
National Institute of Neuroscience, NCNP
Department of Immunology
4-1-1, Ogawahigashi, Kodaira, Tokyo 187-8502, Japan
042-341-2711
yamamura@ncnp.go.jp
Department of Immunology, National Institute of Neuroscience, NCNP
Ministry of Health, Labour and Welfare
NO
2011 | Year | 07 | Month | 08 | Day |
Partially published
Completed
2011 | Year | 06 | Month | 30 | Day |
2011 | Year | 07 | Month | 01 | Day |
2012 | Year | 10 | Month | 11 | Day |
2012 | Year | 10 | Month | 11 | Day |
2013 | Year | 03 | Month | 31 | Day |
2013 | Year | 03 | Month | 31 | Day |
2011 | Year | 06 | Month | 30 | Day |
2014 | Year | 11 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006933
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |